Is clinical development prepared for the paradigm shift caused by COVID-19?
The COVID-19 pandemic has – without warning – turned clinical operations on its head, forcing the clinical research community to re-evaluate how to manage clinical trials. Global Biopharmaceutical companies, medical device companies, and contract research organizations (CROs) were surveyed to explore the impact of the current environment on clinical trial management, providing invaluable insight into:
- The acceleration of adoption of decentralized clinical trial methods.
- Concerns around data collection and remote technology.
- Regulatory guidance surrounding decentralized trials and data collection.